In 2012, seized capsules containing white powder were analyzed to show the presence of unknown steroid-related compounds. Subsequent GC-MS and NMR investigations identified a mixture of 3-and 3-isomers of the novel compound; 3-chloro-17-methyl-5-androstan-17-ol. Synthesis of authentic reference materials followed by comparison of NMR, GC-MS and GC-MS-MS data confirmed the finding of a new "designer" steroid.
column was initially held 180 °C for 0.2 min, then was increased at 5 °C/min to 235 °C, 15 °C/min to 265 °C, then finally 25 °C/min to 300 °C and held for 10 min. Head pressure was programmed to maintain a constant flow rate of 1.2 mL/min. The MS transfer line was set at 300 °C and the ion source was operated in EI+ mode with an ionization energy of 70 eV.
Data was acquired in scan mode (m/z 50 to 650) using Agilent ChemStation ® software.
Purification of seized material
The combined contents of three seized capsules (1.04 g) were extracted in 10 mL of methanol with sonication. The methanol extract was filtered and evaporated to dryness under nitrogen.
The residue was taken up in 1 mL of the eluant solution (10% ethyl acetate/n-hexane) and loaded on to a silica gel (Kieselgel 60, 0.2-0.5mm, Merck) column of approximate dimensions 10 cm x 2 cm (id). Fraction collection commenced after the band had progressed five centimeters. A mixture of compounds (3) and (6) was recovered (approximately 6 mg) from fractions [29] [30] [31] [32] [33] [34] [35] , which were evaporated under nitrogen.
Synthesis of reference materials
Synthesis of 17-methyl-5-androstane-317-diol and 17-methyl-5-androstane-317-diol used in this study was described previously by McKinney et al. [22] Melting points were determined using a SRS Optimelt MPA 100 melting point apparatus and are uncorrected.
Optical rotations were determined using a Perkin-Elmer 241MC polarimeter (sodium D line at 25 °C). Low-resolution mass spectrometry (LRMS) and high-resolution mass spectrometry (HRMS) were performed using positive electron ionization (+EI) on a Micromass VG Autospec mass spectrometer at the Australian National University Mass spectrometry facility.
IR spectra were recorded using a Bruker Alpha FT-IR Spectrometer and peaks are reported in wavenumbers (cm -1 ) and described as follows: br = broad, s = strong, m = medium, w = weak, with assignment of major bands.
Synthesis of 3-chloro-17-methyl-5-androstan-17-ol reference materials
The target 3-chloro-17α-methyl-5α-androstan-17β-ols had not been previously reported in the literature. They could be accessed by methylation of the corresponding known 3-chloro-5α-androstan-17-ones [23] which in turn could be synthesized from the 3-hydroxy-5α-androstan-17-ones by chlorination with inversion of configuration at the reacting center. [24] To this end epiandrosterone (1) underwent chlorination to afford 3α-chloro-5α-androstan-17-one (2) [23] in 79% yield (Figure 1 ). Methylation of this compound provided 3α-chloro-17α-methyl-5α-androstan-17β-ol (3) in 56% yield. The identity and stereochemistry of this compound was confirmed by X-ray crystallography (Supporting Information, Figure S10 ). [25] In a similar manner, androsterone (4) underwent chlorination to afford 3β-chloro-5α-androstan-17-one (5) [23] in 27% yield followed by methylation to give 3β-chloro-17α-methyl-5α-androstan-17β-ol (6) in 32% yield. Detailed synthesis conditions and results are provided in Supporting
Information.
Synthesis of 16-hydroxylated reference materials
The synthesis of the 16-hydroxylated reference materials was completed as outlined in Figure 2 . Formation of the enol acetate (7) from ketone (2) followed by a sequence involving epoxidation, rearrangement and acetylation afforded the acetoxy-ketone (8). Subjecting this material to Grignard reaction with methylmagnesium bromide gave a separable mixture of 3-chloro-17-methyl-5-androstane-16,17-diol (9) and 3-chloro-17-methyl-5-androstane-16,17-diol (10) in a 6.5:1 ratio. Detailed synthesis conditions and results are provided in Supporting Information.
In vitro androgen bioassays
The in vitro yeast and mammalian (HuH7 and HEK293) cell androgen bioassays have been previously described by Akram et al. [27] For the yeast cell androgen bioassay, early to midlog phase yeast cells were sub-cultured into 24-well plates (500 µL/well) and androgen receptor (AR) expression activated with 1 µM CuSO 4 . Cells were then treated with steroids (5 µL/well) over a concentration range to generate a sigmoidal dose curve used to calculate the EC 50 of the steroid response. Treatment continued overnight at 30 °C with vigorous orbital shaking (300 rpm). Yeast cell growth was stalled by ice treatment for 30 min. The optical density (600 nm) was measured then cells were lysed and assayed for β-galactosidase activity using a standard assay. For the mammalian cell androgen bioassay, HuH7 and HEK293 cells were seeded in 96-well plates (1x105 cells/mL) and allowed to recover overnight in phenol red-free DMEM supplemented with 10% charcoal-stripped FCS, Lglutamine and 5.5 µg/mL puromycin. Cells were then treated with steroids over a concentration range to generate a sigmoidal dose response curve. Cells were heated for 35 min at 65 °C to deactivate endogenous alkaline phosphatase before SEAP activity was measured using a commercially available assay (Clontech Laboratories, CA, USA). The EC 50
for both the yeast and mammalian cell-based assays was determined from a sigmoidal curve fit using GraphPad.
In-vitro metabolism studies
A solution containing -NAD (1.5 mM), magnesium chloride (4.5 mM), glucose-6-phosphate acetonide-TMS derivatives to investigate C 16 -C 17 stereochemistry using a modified version of the procedure described by Houghton and Dumasia, [28] specifically the reaction of acetone (0.5 mL) and trifluoroacetic acid (50 L) at 55 °C for 60 min, drying under N 2 at 60 °C, followed by TMS-ether formation. The final extracts were dried under nitrogen at 60 °C before being reconstituted in n-dodecane (50 L) for GC-MS-MS analysis. Control experiments were performed in parallel in the absence of (a) cofactor regeneration (-NAD, magnesium chloride, glucose-6-phosphate and glucose-6-phosphate dehydrogenase), (b) equine or human liver S9 fraction and (c) steroid (3-chloro-17-methyl-5-androstan-17-ol).
Isolation of steroids from urine
Urine (3 mL) aliquots were fortified with d 3 T (1 g/mL, 30 L) as surrogate before adjustment to pH 6 (±0.2) with the addition of 10% HCl. Enzyme hydrolysis was performed using -glucuronidase K12 from E.coli (20 L) overnight at 37 °C. Urinary steroids were isolated by solid phase extraction using ABS Elut NEXUS ® extraction columns (60 mg, 3 cc, Agilent Technologies, Lake Forest, CA, USA) that were conditioned with methanol (3 mL) and water (3 mL) before loading with sample, washed with 0.1 M NaOH (1 mL) and water (3 mL) before elution with methanol (3 mL). The eluates were evaporated to dryness under nitrogen at 60 °C. Equine urine samples were then subjected to chemical hydrolysis with 
In vitro androgen bioassays
Results from Yeast, HEK293 and HuH7 androgen receptor bioassays are summarized in Table 1 . In the yeast androgen bioassay, compared with testosterone (T) and dihydrotestosterone (DHT) over the range of 10 -4 M to 10 -10 M, both isomers displayed androgenic bioactivity with the 3-chloro-17-methyl-5-androstan-17-ol having a similar potency to T but less than DHT whereas the 3-chloro-17-methyl-5-androstan-17-ol isomer had low relative potency. No cellular toxicity was observed for either isomer.
HEK293 cells, a human embryonic kidney cell line, express limited levels of steroid metabolizing enzymes. Both isomers displayed androgenic bioactivity with the 3-chloro-17-methyl-5-androstan-17-ol comparable to T but an order of magnitude more potent than the 3-chloro-17-methyl-5-androstan-17-ol isomer. Neither isomer showed any cellular toxicity.
HuH7, human liver cell line, cells express steroid metabolizing enzymes at higher levels than HEK293 cells. Both 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstan-17-ol displayed androgenic bioactivity in similar relative proportions to their bioactivity in the HEK293 cell line.
In-vitro metabolic analysis
A predictive MS strategy, based on results from previous studies investigating equine metabolism of 17-methyltestosterone and mestanolone, [22, 33] and human endogenous steroids, [34] was applied to identify candidate products from incubation with equine and human S9 fractions that required further investigation by GC-MS-MS. Precursor ions selected for TMS derivatives for mono-, bis-and tris-hydroxylated steroids considered to be potentially formed from 3-chloro-17-methyl-5-androstan-17-ol starting material are provided in Table 2 .
Equine S9 fraction
Product ion experiments targeting m/z 484 identified a response at Rt=15.46 min that indicated the 3-chloro substituent of the parent steroid was conserved. Control experiments showed no presence of this response in the absence of co-factor, equine S9 liver microsomes or parent steroid. Putative identification of 3-chloro-17-methyl-5-androstane-16,17-diol was based on 1.) the presence of m/z 231 reported by McKinney et al. [22] and Schoene et al. [31] to be diagnostic of C 16 -hydroxylated metabolites of 17-methyltestosterone, and 2.)
unsuccessful formation of the cis-acetonide derivative supporting 16-stereochemistry. [28] The identity of 3-chloro-17-methyl-5-androstane-16,17-diol was confirmed by comparison of the equine S9 fraction to the synthesized reference material (Figure 6 ). The 
Translation to routine doping control
Product ion scan experiments were used to optimize collision energies for MRM transitions corresponding to 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstane-16,17-diol that could be included with 17-methyl-5-androstane-3,17-diol into routine anabolic steroid screening (Table 3 ). The limit of detection (LOD) for each steroid was determined from triplicate analysis of three authentic blank equine and human urine samples together with steroid spikes (n=3) of the same urine samples at concentrations of 0.1, 0.2, 0.5, 1, 2, 5 and 10 ng/mL. and 17-methyl-5-androstane-3,17-diol (21-24%). Recoveries observed from spiking of human urine samples were far superior; 3-chloro-17-methyl-5-androstan-17-ol (51-56%), 3-chloro-17-methyl-5-androstane-16,17-diol (82-85%) and 17-methyl-5-androstane-3,17-diol (77-81%), indicating acid hydrolysis used in the equine method to be the likely cause.
The estimated LOD of 0.5 ng/mL for the most sensitive transitions of the target analytes provides effective routine screening capability in equine urine. Example chromatograms for 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstane-16,17-diol are provided by Figures 8 and 9 , respectively. The limit of confirmation, however, is determined by the LOD for the least sensitive of a minimum three MRM transitions required to satisfy AORC criteria. [29] This was estimated at 5 ng/mL for 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstane-16,17-diol in equine urine.
GC-MS-MS precursor ion strategies
The work of Thevis and Schӓnzer [32] has been used to develop "untargeted" steroid analysis methods using precursor ion scanning of fragments arising from diagnostic dissociation mechanisms. In addition to the metabolic and translational foci of the current study, the opportunity was taken to evaluate the application of this detection mode to designer steroids and m/z 231). These results supported the potential for precursor ion scanning to identify novel products from in vitro studies.
In equine urine, however, matrix effects were observed to significantly reduce S/N for the target compounds (Table 4) surveyed between 2 ng/mL and 10 ng/mL. The best results were observed for 17-methyl-5-androstane-3,17-diol by monitoring m/z 143. Parent 3-chloro-17-methyl-5-androstan-17-ol using the same ion was poor, even at 10 ng/mL, thereby requiring further work to evaluate m/z 130 as a suitable alternative. Equine metabolite 3-chloro-17-methyl-5-androstane-16,17-diol displayed reasonable precursor ion (m/z 218) sensitivity at concentrations greater than 5 ng/mL (Figure 10 ).
Inclusion of m/z 169 into a precursor ion scan strategy will be important for identifying unknown steroids containing a C 17 -ketone moiety.
[35]
Discussion
The identification of designer steroids by anti-doping laboratories has to date relied on investigative testing of bulk materials seized and submitted by law enforcement agencies or acquired via ad-hoc procurement. The former identified 3/-chloro-17-methyl-5-androstan-17-ol using underivatized and TMS full-scan GC-MS, 1 H NMR and 13 C NMR techniques. These findings were confirmed following underivatized and TMS full-scan GC-MS comparison to synthesized reference materials of both isomers.
Investigations of designer steroids should include an assessment of androgenic bioactivity to assess the likelihood of misuse and to therefore prioritize the investment required to develop detection methods. Using a panel of yeast and mammalian host cell in vitro androgen bioassays providing a complementary rapid and sensitive appraisal of androgen activity, it was shown that both 3-chloro-17-methyl-5-androstan-17-ol and 3-chloro-17-methyl-5-androstan-17-ol are androgens, with the former having higher intrinsic androgenic activity. In addition, both are likely to be relatively resistant to either activating or inactivating metabolism in the body after ingestion. To explore metabolism effects, both isomers were assessed for bioactivity in the HEK293 and HuH7 androgen bioassays to show expression of steroid metabolizing enzymes, while retaining similar relative potencies and therefore indicating little impact of mammalian cell metabolism. In considering the likely potency of these isomers in vivo, other relevant factors including species-specific metabolism (as illustrated by the diagnostic metabolite profiles in horse and man) and circulating half-life, which is largely determined by its binding to sex-hormone binding globulin, need to be assessed but are undefined at present.
Having identified the novel steroid(s) and assessed the potency to support a target likely for misuse, in vitro and/or in vivo metabolic studies can be performed. Owing to the halogenation of the target steroid in this study, only the former was employed to mitigate any risk to animal and human welfare. This was conducted using the microsomal S9 fractions for equine and human metabolism of 3-chloro-17-methyl-5-androstan-17-ol and identified the major metabolites; 3-chloro-17-methyl-5-androstane-16,17-diol and 17-methyl-5-androstane-3,17-diol, respectively.
Conservation of the chlorine substituent highlights the diagnostic potential of the equine metabolite. The discrete equine and human in vitro metabolism will require further investigation in vivo should the toxicity of 3-chloro-17-methyl-5-androstan-17-ol prove to be negligible and therefore safe for administration. Indeed, limitations need to be considered in assuming correlation of in vitro and in vivo experiments. [36] For example, additional hydroxylation may be expected in vivo, with the potential to provide longer detection periods. Conceivably, 3-chloro-17-methyl-5-androstan-17-ol could be metabolized to 17-methyl-5-androstan-3,16,17-triol. Furthermore, the excretion of parent steroid in vivo cannot be discounted and so has been included in the routine screening method.
While there is merit to the adoption of precursor ion strategies for complementary This research provides an example for anti-doping laboratories to respond to the threat of designer steroids in animal or human sports. The greatest challenge can be to first obtain intelligence as to what illegitimate products may be available and therefore misused. The internet can be useful for this purpose, however, resource limitations preclude comprehensive reviews by the doping control community at any given time. To alleviate this problem, collaboration with forensic drug laboratories performing evidentiary analysis for law-enforcement agencies can provide intelligence of relevant designer drug targets for investigation. 
